Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Merck & Co (NY: MRK )

102.92 +1.75 (+1.73%)
Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,208,062
Open 101.48
Bid (Size) 103.00 (1)
Ask (Size) 103.15 (3)
Prev. Close 101.17
Today's Range 101.00 - 103.23
52wk Range 98.60 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks Poised for a Breakout
All 3 stocks are high on my watchlist. 
Via The Motley Fool
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political

Performance

YTD
-9.11%
-9.11%
1 Month
-5.92%
-5.92%
3 Month
-9.31%
-9.31%
6 Month
-20.40%
-20.40%
1 Year
+1.51%
+1.51%

More News

Read More
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
Via The Motley Fool
Why NYSE:MRK is a Top Pick for Dividend Investors.
Via Chartmill
Is Merck Stock a Buy?
Via The Motley Fool
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom
Via Benzinga
Merck to Participate in the UBS Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
Via The Motley Fool
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Via Benzinga
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Via MarketBeat
Exposures Product Safety
Is Pfizer Stock a Bargain for Long-Term Investors?
Via The Motley Fool
Is It Time to Buy October's Worst-Performing Dow Jones Stocks?
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Magnificent Stocks Under $100 to Buy in November
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Via The Motley Fool
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
Via Benzinga
Merck (MRK) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Merck Q3 Earnings And Revenues Top Estimates
Via Talk Markets
Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Via Benzinga
Will Merck's Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses?
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.